Activin-ActRII antagonists and uses for treating bone and other disorders
Provided herein are methods for the treatment of bone disorders that are associated with kidney disease wherein the methods comprise administration of Activin-ActRIIA inhibitors to a subject in need of the treatment. Also provided herein are methods and compositions for the treatment of low turnover bone disorders wherein the methods comprise administration of Activin-ActRIIA inhibitors to a subject in need of the treatment. Further provided herein are compositions for the treatment of bone disorders that are associated with kidney disease and compositions for the treatment of low turnover bone disorders and vascular calcification.
1. A method for treating vascular calcification in a subject in need thereof, wherein the method comprises administering a therapeutically effective amount of an ActRIIA inhibitor to the subject, wherein the ActRIIA inhibitor is a polypeptide comprising an amino acid sequence selected from the group consisting of:
a. 90% identical to SEQ ID NO:2;
b. 95% identical to SEQ ID NO:2;
c. 98% identical to SEQ ID NO:2;
d. SEQ ID NO:2;
e. 90% identical to SEQ ID NO:3;
f. 95% identical to SEQ ID NO:3;
g. 98% identical to SEQ ID NO:3;
h. SEQ ID NO:3;
i. 90% identical to SEQ ID NO:6;
j. 95% identical to SEQ ID NO:6;
k. 98% identical to SEQ ID NO:6;
l. SEQ ID NO:6;
m. 90% identical to SEQ ID NO:7;
n. 95% identical to SEQ ID NO:7;
o. 98% identical to SEQ ID NO:7;
p. SEQ ID NO:7;
q. 90% identical to SEQ ID NO:12;
r. 95% identical to SEQ ID NO:12;
s. 98% identical to SEQ ID NO:12; and
t. SEQ ID NO:12.
2. A method for reducing vascular calcium levels in a subject diagnosed with vascular calcification, wherein the method comprises administering a therapeutically effective amount of an ActRIIA inhibitor to the subject, wherein the ActRIIA inhibitor is a polypeptide comprising an amino acid sequence selected from the group consisting of:
a. 90% identical to SEQ ID NO:2;
b. 95% identical to SEQ ID NO:2;
c. 98% identical to SEQ ID NO:2;
d. SEQ ID NO:2;
e. 90% identical to SEQ ID NO:3;
f. 95% identical to SEQ ID NO:3;
g. 98% identical to SEQ ID NO:3;
h. SEQ ID NO:3;
i. 90% identical to SEQ ID NO:6;
j. 95% identical to SEQ ID NO:6;
k. 98% identical to SEQ ID NO:6;
l. SEQ ID NO:6;
m. 90% identical to SEQ ID NO:7;
n. 95% identical to SEQ ID NO:7;
o. 98% identical to SEQ ID NO:7;
p. SEQ ID NO:7;
q. 90% identical to SEQ ID NO:12;
r. 95% identical to SEQ ID NO:12;
s. 98% identical to SEQ ID NO:12; and
t. SEQ ID NO:12.
3. The method of claim 1 , wherein the ActRIIA inhibitor is a polypeptide comprising the amino acid sequence of SEQ ID NO:7.
4. The method of claim 1 , wherein the ActRIIA inhibitor is administered parentally.
5. The method of claim 1 , wherein the subject is less than 18 years old.
6. The method of claim 1 , wherein the method increases the height of the subject.
7. The method of claim 1 , wherein the subject has end stage renal disease.
8. The method of claim 1 , wherein the subject undergoes dialysis.
9. The method of claim 2 , wherein the ActRIIA inhibitor is a polypeptide comprising the amino acid sequence of SEQ ID NO:7.
10. The method of claim 2 , wherein the ActRIIA inhibitor is administered parentally.
11. The method of claim 2 , wherein the subject is less than 18 years old.
12. The method of claim 2 , wherein the method increases the height of the subject.
13. The method of claim 2 , wherein the subject has end stage renal disease.
14. The method of claim 2 , wherein the subject undergoes dialysis.
15. The method of claim 1 , wherein the ActRIIA inhibitor is a polypeptide consisting of the amino acid sequence of SEQ ID NO:7.
16. The method of claim 2 , wherein the ActRIIA inhibitor is a polypeptide consisting of the amino acid sequence of SEQ ID NO:7.